To that end, a previous study performed in our lab to identify potential targets for radioresistant breast cancers nominated Bcl-2 family inhibition as a potential targeted approach to sensitize radioresistant breast cancers to radiotherapy (36). Here, BCL2 is linked to breast carcinoma.